Chronic lymphocytic leukaemia highlights from ASH 2019
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
It’s a great meeting for CLL and a number of themes are being reinforced. So when MURANO was first presented it was the first study exploring time-limited treatment and there was some uncertainty about whether that would a) be effective, and b) whether it would be acceptable to patients. We’re now seeing both in the frontline setting, so the CLL14 study has presented updated data confirming the applicability of time-limited treatment, and we’re seeing other novel combinations, predominantly using venetoclax, attempting to obtain deep remissions with the goal of time-limited treatment. So that treatment paradigm of using combinations, obtaining deep remissions with the goal of time-limited treatment has really been established.
